Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1417315-52-6

7-(4-(trifluoromethyl)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1417315-52-6 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1417315-52-6 Structure

  • Basic information

    1. Product Name: 7-(4-(trifluoromethyl)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one
    2. Synonyms: 7-(4-(trifluoromethyl)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one
    3. CAS NO:1417315-52-6
    4. Molecular Formula:
    5. Molecular Weight: 307.272
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 1417315-52-6.mol

  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: N/A
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: 7-(4-(trifluoromethyl)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one(CAS DataBase Reference)
    10. NIST Chemistry Reference: 7-(4-(trifluoromethyl)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one(1417315-52-6)
    11. EPA Substance Registry System: 7-(4-(trifluoromethyl)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one(1417315-52-6)

  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 1417315-52-6(Hazardous Substances Data)

1417315-52-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1417315-52-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,1,7,3,1 and 5 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1417315-52:
(9*1)+(8*4)+(7*1)+(6*7)+(5*3)+(4*1)+(3*5)+(2*5)+(1*2)=136
136 % 10 = 6
So 1417315-52-6 is a valid CAS Registry Number.

1417315-52-6Relevant articles and documents

Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late INai), a Phase II Agent with Demonstrated Preclinical Anti-Ischemic and Antiarrhythmic Properties

Zablocki, Jeff A.,Elzein, Elfatih,Li, Xiaofen,Koltun, Dmitry O.,Parkhill, Eric Q.,Kobayashi, Tetsuya,Martinez, Ruben,Corkey, Britton,Jiang, Haibo,Perry, Thao,Kalla, Rao,Notte, Gregory T.,Saunders, Oliver,Graupe, Michael,Lu, Yafan,Venkataramani, Chandru,Guerrero, Juan,Perry, Jason,Osier, Mark,Strickley, Robert,Liu, Gongxin,Wang, Wei-Qun,Hu, Lufei,Li, Xiao-Jun,El-Bizri, Nesrine,Hirakawa, Ryoko,Kahlig, Kris,Xie, Cheng,Li, Cindy Hong,Dhalla, Arvinder K.,Rajamani, Sridharan,Mollova, Nevena,Soohoo, Daniel,Lepist, Eve-Irene,Murray, Bernard,Rhodes, Gerry,Belardinelli, Luiz,Desai, Manoj C.

, p. 9005 - 9017 (2016/10/22)

Late sodium current (late INa) is enhanced during ischemia by reactive oxygen species (ROS) modifying the Nav 1.5 channel, resulting in incomplete inactivation. Compound 4 (GS-6615, eleclazine) a novel, potent, and selective inhibitor of late INa, is currently in clinical development for treatment of long QT-3 syndrome (LQT-3), hypertrophic cardiomyopathy (HCM), and ventricular tachycardia-ventricular fibrillation (VT-VF). We will describe structure-activity relationship (SAR) leading to the discovery of 4 that is vastly improved from the first generation late INa inhibitor 1 (ranolazine). Compound 4 was 42 times more potent than 1 in reducing ischemic burden in vivo (S-T segment elevation, 15 min left anteriorior descending, LAD, occlusion in rabbits) with EC50 values of 190 and 8000 nM, respectively. Compound 4 represents a new class of potent late INa inhibitors that will be useful in delineating the role of inhibitors of this current in the treatment of patients.

COMBINATION THERAPIES USING LATE SODIUM ION CHANNEL BLOCKERS AND POTASSIUM ION CHANNEL BLOCKERS

-

, (2013/08/15)

Described herein is a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising administration of an effective amount of one or more of a potassium channel blocker and an effective amount of one or more of a late sodium channel blocker. Also provided are methods for modulating ventricular and atrial rhythm and rate. Also provided are pharmaceutical formulations that are suitable for such combined administration.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1417315-52-6